Daniel O'Day, a director and officer of Gilead Sciences, filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 112,429 shares of common stock to be acquired through the exercise of stock options.
Key Highlights
- Proposed sale: 112,429 shares of Gilead Sciences common stock, with an aggregate market value of $18,828,484.63, according to the filing.
- Source of shares: The securities are to be acquired through the exercise of stock options, with the acquisition date listed as November 4, 2026.
- Exchange and broker: The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Shares outstanding: The filing reports 1,240,338,614 shares of common stock outstanding.
- 10b5-1 plan: The notice indicates reliance on a Rule 10b5-1 plan adopted on February 25, 2026.
- Prior three-month sales: O'Day sold a combined 60,881 shares in four transactions between September 1, 2026, and November 2, 2026, generating gross proceeds totaling $9,777,278.37, according to the filing.
Daniel O'Day's Proposed Option-Exercise Sale at Gilead Sciences
According to the Form 144 filed on November 4, 2026, Daniel O'Day, identified in the filing as both a director and an officer of the issuer named "GILEAD SCIENCE," is proposing to sell 112,429 shares of common stock on NASDAQ. The filing states that the shares will be received upon the exercise of stock options, with an approximate sale date of November 4, 2026, and payment made in cash on that same date. The aggregate market value of the proposed sale is listed as $18,828,484.63.
The filing discloses that O'Day adopted a written trading plan under Rule 10b5-1 on February 25, 2026. A remark in the filing states: "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale." The filing lists the SEC file number for the issuer as 000-19731 and the issuer's address as 333 Lakeside Drive, Foster City, California 94404.
The filing also details four prior sales of common stock under 10b5-1 plans attributed to O'Day during the three months preceding this notice: 15,000 shares sold on September 1, 2026 for gross proceeds of $2,229,592.50; 15,000 shares sold on October 1, 2026 for $2,218,507.50; 15,881 shares sold on October 30, 2026 for $2,783,075.37; and 15,000 shares sold on November 2, 2026 for $2,546,103.00. The combined gross proceeds from those four transactions total $9,777,278.37, as reported in the filing.
What Was Disclosed
A Form 144 notice was filed by Daniel O'Day, a director and officer of Gilead Sciences, on November 4, 2026, covering a proposed sale of 112,429 shares of common stock sourced from stock option exercises, with an aggregate market value of $18,828,484.63, to be executed on NASDAQ under a 10b5-1 plan adopted February 25, 2026.




Please wait processing your request...